Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
December 7th 2023Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.
Read More
Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors
September 19th 2023Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.
Read More
Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC
May 4th 2023Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.
Read More
Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases
April 6th 2023Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.
Read More